Antipsychotic-induced weight gain is a major management problem for clinicians. It has
been shown that weight gain and obesity lead to increased cardiovascular and …

Antipsychotic medications are critical to child and adolescent psychiatry, from the
stabilization of psychotic disorders like schizophrenia, bipolar disorder, and psychotic …

Antipsychotic drugs (APDs) represent a cornerstone in the treatment of schizophrenia and
other psychoses. The effectiveness of the first generation (typical) APDs are hampered by so …

Atypical antipsychotics (AAPs) are the drug of choice in the management of mental illnesses
by virtue of their advantage over typical antipsychotics ie least tendency of producing …

Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the
treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied …

Background and purpose: Insulin resistance (IR) and obesity predispose diseases such as
diabetes, cardiovascular and neurodegenerative disorders. Beta-caryophyllene (BCP), a …

Antipsychotic drugs (APDs) are widely prescribed to control various mental disorders. As
mental disorders are chronic diseases, these drugs are often used over a life-time. However …

Vestibular compensation is responsible for the spontaneous recovery of postural, locomotor,
and oculomotor dysfunctions in patients with peripheral vestibular lesion or posterior …

Introduction: Patients living with schizophrenia have a marked risk of clinically significant
weight gain and obesity compared to the general population. The risks have been …

The long-term use of antipsychotics (APs) may cause a variety of diseases, such as
metabolic syndrome, antipsychotic-induced weight gain (AIWG), and even obesity. This …